Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)

被引：21

作者：

Mercer, Swati P. ^{[1
]}

Roecker, Anthony J. ^{[1
]}

Garson, Susan ^{[2
]}

Reiss, Duane R. ^{[2
]}

Harrell, C. Meacham ^{[2
]}

Murphy, Kathy L. ^{[2
]}

Bruno, Joseph G. ^{[4
]}

Bednar, Rodney A. ^{[4
]}

Lemaire, Wei ^{[2
]}

Cui, Donghui ^{[3
]}

Cabalu, Tamara D. ^{[3
]}

Tang, Cuyue ^{[3
]}

Prueksaritanont, Thomayant ^{[3
]}

Hartman, George D. ^{[1
]}

Young, Steven D. ^{[1
]}

Winrow, Christopher J. ^{[2
]}

Renger, John J. ^{[2
]}

Coleman, Paul J. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA

[2] Merck Res Labs, Dept Neurosci, West Point, PA 19486 USA

[3] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA

[4] Merck Res Labs, West Point Facil Automat & Screening WP FAST, West Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 24期

关键词：

Orexin receptor antagonists; Selective orexin-2 receptor antagonists; Insomnia; Hypocretin; Rat sleep EEG; P-GLYCOPROTEIN; POTENT; SLEEP; PROMOTION;

D O I：

10.1016/j.bmcl.2013.10.045

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The orexin (or hypocretin) system has been identified as a novel target for the treatment of insomnia due to the wealth of biological and genetic data discovered over the past decade. Recently, clinical proof-of-concept was achieved for the treatment of primary insomnia using dual (OX1R/OX2R) orexin receptor antagonists. However, elucidation of the pharmacology associated with selective orexin-2 receptor antagonists (2-SORAs) has been hampered by the lack of orally bioavailable, highly selective small molecule probes. Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described. A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：6620 / 6624

页数：5

共 50 条

[31] Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate
Letavic, Michael A.
Bonaventure, Pascal
Carruthers, Nicholas I.
Dugovic, Christine
Koudriakova, Tatiana
Lord, Brian
Lovenberg, Timothy W.
Ly, Kiev S.
Mani, Neelakandha S.
Nepomuceno, Diane
Pippel, Daniel J.
Rizzolio, Michele
Shelton, Jonathan E.
Shah, Chandra R.
Shireman, Brock T.
Young, Lana K.
Yun, Sujin
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (14) : 5620 - 5636
[32] Behavioral and polysomnographic characterization of orexin-1 receptor and orexin-2 receptor double knockout mice.
Kisanuki, YY
Chemelli, RM
Tokita, S
Willie, JT
Sinton, CM
Yanagisawa, M
SLEEP, 2001, 24 : A22 - A22
[33] The Role of the Orexin-2 Receptor in the Nucleus Raphe Magnus on Trigeminovascular Nociceptive Transmission
Supronsinchai, W.
Hoffmann, J.
Akerman, S.
Goadsby, P. J.
CEPHALALGIA, 2013, 33 (S8) : 223 - 224
[34] Sleep-inducing effects mediated by a selective orexin-2 receptor antagonist during the light phase in the rat
Shelton, J.
Sutton, S.
Yun, S.
Li, S.
Dvorak, C.
Carruthers, N.
Lovenberg, T.
Dugovic, C.
JOURNAL OF SLEEP RESEARCH, 2008, 17 : 201 - 201
[35] Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists
Williams, Jodi T.
Gatfield, John
Roch, Catherine
Treiber, Alexander
Jenck, Francois
Bolli, Martin H.
Brotschi, Christine
Sifferlen, Thierry
Heidmann, Bibia
Boss, Christoph
MEDCHEMCOMM, 2015, 6 (06) : 1054 - 1064
[36] Discovery of MK-3697: A selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia
Roecker, Anthony J.
Reger, Thomas S.
Mattern, M. Christa
Mercer, Swati P.
Bergman, Jeffrey M.
Schreier, John D.
Cube, Rowena V.
Cox, Christopher D.
Li, Dansu
Lemaire, Wei
Bruno, Joseph G.
Harrell, C. Meacham
Garson, Susan L.
Gotter, Anthony L.
Fox, Steven V.
Stevens, Joanne
Tannenbaum, Pamela L.
Prueksaritanont, Thomayant
Cabalu, Tamara D.
Cui, Donghui
Stellabott, Joyce
Hartman, George D.
Young, Steven D.
Winrow, Christopher J.
Renger, John J.
Coleman, Paul J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (20) : 4884 - 4890
[37] Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor
Oi, Norihito
Suzuki, Michiyuki
Terauchi, Taro
Tokunaga, Masaki
Nakatani, Yosuke
Yamamoto, Noboru
Fukumura, Toshimitsu
Zhang, Ming-Rong
Suhara, Tetsuya
Higuchi, Makoto
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (16) : 6371 - 6385
[38] Development of Novel 11C-Labeled Selective Orexin-2 Receptor Radioligands for Positron Emission Tomography Imaging
Rong, Jian
Yamasaki, Tomoteru
Li, Yinlong
Kumata, Katsushi
Zhao, Chunyu
Haider, Ahmed
Chen, Jiahui
Xiao, Zhiwei
Fujinaga, Masayuki
Hu, Kuan
Mori, Wakana
Zhang, Yiding
Xie, Lin
Zhou, Xin
Collier, Thomas L.
Zhang, Ming-Rong
Liang, Steven
ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (10): : 1419 - 1426
[39] BLOCKADE OF OREXIN-I RECEPTORS ATTENUATES OREXIN-2 RECEPTOR ANTAGONISM INDUCED SLEEP PROMOTION IN THE RAT
Dugovic, C.
Shelton, J.
Aluisio, L.
Fraser, I
Sutton, S.
Pascal, B.
Yun, S.
Li, X.
Dvorak, C.
Lovenberg, T.
SLEEP, 2009, 32 : A1 - A1
[40] Interaction modes of human orexin 2 receptor with selective and nonselective antagonists studied by NMR spectroscopy
Imamura, Kayo
Akagi, Ken-Ichi
Miyanoiri, Yohei
Tsujimoto, Hirokazu
Hirokawa, Takatsugu
Ashida, Hideo
Murakami, Kaori
Inoue, Asuka
Suno, Ryoji
Ikegami, Takahisa
Sekiyama, Naotaka
Iwata, So
Kobayashi, Takuya
Tochio, Hidehito
STRUCTURE, 2024, 32 (03) : 352 - 361.e5

← 1 2 3 4 5 →